Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Prospective Observation on the Use of Von Willebrand Factor (VWF) Concentrates in a Large Cohort of Type 3 Von Willebrand Disease (VWD): Interim (18-months) Analyses on 149 Cases Enrolled into the 3Winters-Ips Project

Blood (2018) 132 (Supplement 1): 2464.

https://doi.org/10.1182/blood-2018-99-112447

Published: 2018

Journal Articles

Clustering of Bleeding Symptoms in Patients Previously Diagnosed As Type 3 Von Willebrand Disease: Results from a Large Cohort of Type 3 Von Willebrand Disease (the 3Winters-Ips Project)

Blood (2018) 132 (Supplement 1): 2465.

https://doi.org/10.1182/blood-2018-99-113996

Published: 2018

Journal Articles

Variability in Bleeding Phenotype in Type 3 VWD Families

Pamela A Christopherson, Veronica H Flood, MD, Sandra L Haberichter, PhD, Joan Cox Gill, MD, Robert R Montgomery, MD, Zimmerman Program Investigators

Blood (2018) 132 (Supplement 1): 2466.

https://doi.org/10.1182/blood-2018-99-112961

Published: 2018

Journal Articles

Profile of Mutations Identified in the 3WINTERS-IPS Project on European & Iranian Patients with Previously Diagnosed Type 3 Von Willebrand Disease.

Luciano Baronciani, PhD, Flora Peyvandi, MD PhD, Anne Goodeve, PhD, Reinhard Schneppenheim, MDPhD, Zahra Badiee, Mohammad-Reza Baghaipour, Javier Battle, Erik Berntorp, MD PhD, Imre Bodó, MD PhD, Ulrich Budde, MD, Andrea Cairo, PhD, Giancarlo Castaman, Laura Crookes, Jeroen C.J. Eikenboom, MD, Peyman Eshghi, MD, Cosimo Ettorre, MD, Jenny Goudemand, MD PhD, Wolf Hassenpflug, Charles Richard Morris Hay, MDFRCP,FRCPath, Hamid Hoorfar, MD, Mehran Karimi, MD, Bijan Keikhaei, Riitta Lassila, MD PR, Frank W.G. Leebeek, MD PhD, Maria Fernanda Lopez Fernandez, Pier Mannuccio Mannucci, MD, Maria Gabriella Mazzucconi, MD, Massimo Morfini, MD, Nikolas Nikšić, Johannes Oldenburg, Florian Oyen, Rafael Parra Lòpez, Ian Peake, PhD, Gholamreza Toogeh, Alberto Tosetto, Marc Trossaert, Sayed Omid Reza Zekavat, MD, Eva M.K. Zetterberg, MD PhD, Augusto B Federici, MD

Blood (2018) 132 (Supplement 1): 1184.

https://doi.org/10.1182/blood-2018-99-114702

Published: 2018

Journal Articles

A Unique Case of Type 3 Von Willebrand Disease

Mamatha Mandava, MD, John Lazarchick, MD, Emily Curl, Shayla Bergmann, MD

Blood (2018) 132 (Supplement 1): 5031.

https://doi.org/10.1182/blood-2018-99-112976

Published: 2018

Journal Articles

von Willebrand factor regulation of blood vessel formation

Anna M. Randi, Koval E. Smith, Giancarlo Castaman

Blood (2018) 132 (2): 132–140.

https://doi.org/10.1182/blood-2018-01-769018

Published: 2018

Journal Articles

Genotype-Phenotype Relationship and the Role of Alloantibodies in Type 3 VWD in the Zimmerman Program

Pamela A Christopherson, Crystal L Perry, Daniel B. Bellissimo, PhD, Veronica H Flood, MD, Joan Cox Gill, MD, Sandra L Haberichter, PhD, Robert R. Montgomery, MD, Zimmerman Program Investigators

Blood (2017) 130 (Supplement 1): 19.

https://doi.org/10.1182/blood.V130.Suppl_1.19.19

Published: 2017

Journal Articles

Centralized Laboratory Testing for Inhibitors in the U.S. Hemophilia Treatment Centers Network: Testing Protocol and Results on 10,178 Specimens

Connie H Miller, PhD, Dorothy Ellingsen, Jennifer Driggers, Brian Boylan, Amanda B. Payne, MPH, Fiona Bethea, MPH, Vanessa R Byams, MPH, J. Michael Soucie, PhD, Christopher J. Bean, PhD

Blood (2017) 130 (Supplement 1): 3692.

https://doi.org/10.1182/blood.V130.Suppl_1.3692.3692

Published: 2017

Journal Articles

Characterization of Bleeding in Hemophilia Carriers and Comparison to Women with Type 1 Von Willebrand Disease, Type 3 Von Willebrand Disease Obligate Carriers and Controls

Natasha Amrita Satkunam, MBBS, MSc, Johnny Mahlangu, MD, Christoph Bidlingmaier, MD PD, Dr. MD, Maria Eva Mingot-Castellano, PhD, Meera B. Chitlur, MD, Patrick F. Fogarty, MD, Adam Cuker, MD MS, Maria Elisa Mancuso, MD PhD, Pal André Holme, PhD MD, Julie Grabell, BA, CCRP, Wilma Hopman, MA, Prasad Mathew, MD, Paula D. James, MD

Blood (2016) 128 (22): 875.

https://doi.org/10.1182/blood.V128.22.875.875

Published: 2016

Journal Articles

Type 3 Von Willebrand Disease: A Case Report of a Rare Entity

Stephanie Phillips, DO, John Lazarchick, MD, Shayla Bergmann, MD

Blood (2016) 128 (22): 4988.

https://doi.org/10.1182/blood.V128.22.4988.4988

Published: 2016

Journal Articles

Molecular Basis of Von Willebrand Disease in Patients from India

Sumitha Elayaperumal, M.Sc, Eunice Sindhuvi Edison, PhD, Sankari Devi Govindanattar, B.Sc, Surendar Singh, B.Sc, Aby Abraham, MD DM, Biju George, DM, Auro Viswabandya, MD DM, Sukesh Nair, MD FRCPA, Alok Srivastava, MD FRACP

Blood (2015) 126 (23): 1102.

https://doi.org/10.1182/blood.V126.23.1102.1102

Published: 2015

Journal Articles

Establishment of Blood Outgrowth Endothelial Cells from a Type 3 Von Willebrand Disease (VWD) Patient with a Neutralizing Anti-VWF Inhibitors

Naomi Sanda, MSc, Nobuaki Suzuki, MD PhD, Mayuko Kishimoto, MD, Natsumi Kameyama, Yoko Kajiura, Hiroyuki Matsumoto, Shigeo Nakamura, MD PhD, Tadashi Matsushita, MD PhD

Blood (2014) 124 (21): 1508.

https://doi.org/10.1182/blood.V124.21.1508.1508

Published: 2014

Journal Articles

Tonsillectomy in a Patient with Type 3 Von Willebrand Disease

Emily K. Rimmer, MD, Dawn Zawadski, Tracy Voth, Michael Gousseau, MD, Donald S Houston, MD PhD

Blood (2014) 124 (21): 5067.

https://doi.org/10.1182/blood.V124.21.5067.5067

Published: 2014

Journal Articles

Heterogeneity Of Type 3 Von Willebrand Disease (VWD): Evidence From Patient-Derived Blood Outgrowth Endothelial Cells (BOEC)

Mackenzie L. Bowman, MSc, Lara J. Casey, Lindsey G. Hawke, Paula D. James, MD

Blood (2013) 122 (21): 3517.

https://doi.org/10.1182/blood.V122.21.3517.3517

Published: 2013

Journal Articles

Comparative Cellular Studies of the VWF Exon 4–5 Deletion Mutation Using Patient-Derived Blood Outgrowth Endothelial Cells (BOEC) and Megakaryocytes

Mackenzie L Bowman, MSc, Ling Li, MD, Fred Pluthero, PhD, Hilary Christensen, Irwin Walker, MBBS, Walter H. Kahr, MD, PhD, Paula D. James, MD

Blood (2012) 120 (21): 1076.

https://doi.org/10.1182/blood.V120.21.1076.1076

Published: 2012

Journal Articles

A Large-Pore IEF Gel Electrophoresis Separates the Complex in Both of ADAMTS13 Bound to VWF and to the IgG Autoantibodies From the Unbound in Plasma Milieu

Masanori Matsumoto, MD, PhD, Ayami Isonishi, BS, Yuji Hori, BS, Masaki Hayakawa, MD, Kenji Soejima, PhD, Yoshihiro Fujimura, MD, PhD

Blood (2011) 118 (21): 1160.

https://doi.org/10.1182/blood.V118.21.1160.1160

Published: 2011

Journal Articles

Recombinant Human Von Willebrand Factor (rhVWF): First-In-Human Study Evaluating Pharmacokinetics, Demonstrating Safety and Tolerability In Type 3 Von Willebrand Disease

Tobias Suiter, MD, Michael Laffan, DM, FRCP, FRCPath, Pier M. Mannucci, MD, Christine L. Kempton, MD, MSc, Edward H Romond, MD, Amy D. Shapiro, MD, Ingvild Birschmann, MD, PhD, Joan Cox Gill, MD, Margaret V. Ragni, MD, MPH, Peter Turecek, PhD, Bruce M. Ewenstein, MD, PhD, VrWF Study Team Baxter BioScience

Blood (2010) 116 (21): 237.

https://doi.org/10.1182/blood.V116.21.237.237

Published: 2010

Journal Articles

Type 3 Von Willebrand Disease with Alloantibodies and Its Challenging Management During Episode of Bleeding

Anupam Verma, MD, Hassan Yaish, MD, George M. Rodgers, MD, PhD

Blood (2010) 116 (21): 1405.

https://doi.org/10.1182/blood.V116.21.1405.1405

Published: 2010

Journal Articles

Use of Rituximab in Patients with Congenital Bleeding Disorders and High Titre Inhibitors.

Julie Curtin, MBBS, PhD, FRACP, FRCPA, Juliana Teo, MBBS, FRCPA, FRACP, Robyn Shoemark, RN, Kilo Tatjana, MD, Catherine Harris, MBBS, FRCPA, Boyd Webster, MBBS, FRCPA, Ahti Lammi, MBBS, FRACP, FRCPA

Blood (2009) 114 (22): 3501.

https://doi.org/10.1182/blood.V114.22.3501.3501

Published: 2009

Journal Articles

The Use of High Resolution Melting (HRM) Analysis for Molecular Gene Defects of Type 3 Von Willebrand Disease: Studies of An Italian Cohort of 10 Patients.

Maria Solimando, Augusto B. Federici, Luciano Baronciani, Alberto Mussetti, Margherita Punzo, Silvia La Marca, Manuela Platè, Rosanna Asselta, Pier Mannuccio Mannucci

Blood (2009) 114 (22): 3498.

https://doi.org/10.1182/blood.V114.22.3498.3498

Published: 2009

NARROW

Prospective Observation on the Use of Von Willebrand Factor (VWF) Concentrates in a Large Cohort of Type 3 Von Willebrand Disease (VWD): Interim (18-months) Analyses on 149 Cases Enrolled into the 3Winters-Ips Project

Clustering of Bleeding Symptoms in Patients Previously Diagnosed As Type 3 Von Willebrand Disease: Results from a Large Cohort of Type 3 Von Willebrand Disease (the 3Winters-Ips Project)

Variability in Bleeding Phenotype in Type 3 VWD Families

Profile of Mutations Identified in the 3WINTERS-IPS Project on European & Iranian Patients with Previously Diagnosed Type 3 Von Willebrand Disease.

A Unique Case of Type 3 Von Willebrand Disease

von Willebrand factor regulation of blood vessel formation

Genotype-Phenotype Relationship and the Role of Alloantibodies in Type 3 VWD in the Zimmerman Program

Centralized Laboratory Testing for Inhibitors in the U.S. Hemophilia Treatment Centers Network: Testing Protocol and Results on 10,178 Specimens

Characterization of Bleeding in Hemophilia Carriers and Comparison to Women with Type 1 Von Willebrand Disease, Type 3 Von Willebrand Disease Obligate Carriers and Controls

Type 3 Von Willebrand Disease: A Case Report of a Rare Entity

Molecular Basis of Von Willebrand Disease in Patients from India

Establishment of Blood Outgrowth Endothelial Cells from a Type 3 Von Willebrand Disease (VWD) Patient with a Neutralizing Anti-VWF Inhibitors

Tonsillectomy in a Patient with Type 3 Von Willebrand Disease

Heterogeneity Of Type 3 Von Willebrand Disease (VWD): Evidence From Patient-Derived Blood Outgrowth Endothelial Cells (BOEC)

Comparative Cellular Studies of the VWF Exon 4–5 Deletion Mutation Using Patient-Derived Blood Outgrowth Endothelial Cells (BOEC) and Megakaryocytes

A Large-Pore IEF Gel Electrophoresis Separates the Complex in Both of ADAMTS13 Bound to VWF and to the IgG Autoantibodies From the Unbound in Plasma Milieu

Recombinant Human Von Willebrand Factor (rhVWF): First-In-Human Study Evaluating Pharmacokinetics, Demonstrating Safety and Tolerability In Type 3 Von Willebrand Disease

Type 3 Von Willebrand Disease with Alloantibodies and Its Challenging Management During Episode of Bleeding

Use of Rituximab in Patients with Congenital Bleeding Disorders and High Titre Inhibitors.

The Use of High Resolution Melting (HRM) Analysis for Molecular Gene Defects of Type 3 Von Willebrand Disease: Studies of An Italian Cohort of 10 Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only